Other languages OncoCyte Corporation

Equities

OCX

US68235C2061

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
2.55 ^USD	+2.41%		+3.66%	+2.00%

04-25	OncoCyte Corporation announced that it has received $15.807655 million in funding	CI
04-16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Broadwood Capital, Inc. Engages with OncoCyte Corporation	04-16
Sector Update: Health Care Stocks Steady Pre-Bell Friday	04-12
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-12
OncoCyte Agrees to $15.8 Million Private Placement of Stock, Warrants	04-12
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	04-11
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays	12-06
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Sector Update: Health Care Stocks Steady Late Afternoon	28/08/23
Sector Update: Health Care Stocks Rising in Afternoon Trading	28/08/23
OncoCyte Says VitaGraft Kidney Diagnostic Test to Receive Medicare, Medicaid Coverage	28/08/23
Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage	28/08/23
OncoCyte Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients	25/07/23
OncoCyte Approves 1-for-20 Reverse Split of Common Stock; Shares Down	24/07/23
Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation	19/05/23
OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Oncocyte Cuts Workforce by 20%	12/04/23
Oncocyte Corporation Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer	07/04/23
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
OncoCyte Names Joshua Riggs Chief Executive	02/03/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages OncoCyte Corporation

Equities

OCX

US68235C2061

Other languages

Filters